
## Guido Ahle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2814959/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life—experience of the French Network. Bone Marrow Transplantation, 2022, 57, 966-974.	2.4	12
2	Chemotherapy is an efficient treatment in primary CNS MALT lymphoma. Journal of Neuro-Oncology, 2022, 159, 151-161.	2.9	3
3	Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study. Hematological Oncology, 2022, 40, 976-986.	1.7	2
4	Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML. European Radiology, 2021, 31, 2944-2955.	4.5	10
5	Late-onset riboflavin transporter deficiency: a treatable mimic of various motor neuropathy aetiologies. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 27-35.	1.9	11
6	Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Critical Reviews in Oncology/Hematology, 2021, 157, 103188.	4.4	17
7	CSF interleukin 6 is a useful marker to distinguish pseudotumoral CNS inflammatory diseases from primary CNS lymphoma. Journal of Neurology, 2021, 268, 2890-2894.	3.6	4
8	Intravenous highâ€dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An <scp>LOC</scp> network study. American Journal of Hematology, 2021, 96, 823-833.	4.1	18
9	Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma. Neurology, 2021, 97, 628-631.	1.1	16
10	Management and outcome of primary CNS lymphoma in the modern era. Neurology, 2020, 94, e1027-e1039.	1.1	125
11	Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19). European Journal of Cancer, 2020, 141, 62-81.	2.8	122
12	Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurology, 2020, 77, 1079.	9.0	357
13	First Results of the Acsé Pembrolizumab Phase II in the Primary CNS Lymphoma (PCNSL) Cohort. Blood, 2020, 136, 15-16.	1.4	18
14	Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study. Journal of Neuro-Oncology, 2019, 144, 419-426.	2.9	10
15	Complementary and alternative medicine use in glioma patients in France. Journal of Neuro-Oncology, 2019, 145, 487-499.	2.9	8
16	P14.49 Primary central nervous system lymphoma presenting as dementia: do not forget IL10 in CSF analysis. Neuro-Oncology, 2019, 21, iii78-iii78.	1.2	0
17	P14.87 Leptomeningeal dissemination in high grade glioma: Correlation of MRI, cytology and standard CSF indices. Neuro-Oncology, 2019, 21, iii88-iii88.	1.2	0
18	OS1.3 Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis. Neuro-Oncology, 2019, 21, iii5-iii6.	1.2	0

Guido Ahle

#	Article	IF	CITATIONS
19	P14.90 Interleukin 6 is a useful marker for pseudotumoral inflammatory CNS lesions suspicious of lymphoma. Neuro-Oncology, 2019, 21, iii89-iii89.	1.2	0
20	CLIPPERS and its mimics: evaluation of new criteria for the diagnosis of CLIPPERS. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1027-1038.	1.9	51
21	A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study. Neuro-Oncology, 2019, 21, 1039-1048.	1.2	13
22	Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions. Journal of Neurology, 2019, 266, 1743-1755.	3.6	9
23	Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis. Acta Neuropathologica Communications, 2019, 7, 43.	5.2	44
24	Primary lymphomatoid granulomatosis in the central nervous system: A report of three cases. Neuropathology, 2019, 39, 168-169.	1.2	1
25	P14.118 Carboxypeptidase G2 (CPG2) rescue after high dose methotrexate (hdMTX) chemotherapy for Primary CNS Lymphoma (PCNSL). A French LOC network study. Neuro-Oncology, 2019, 21, iii96-iii96.	1.2	2
26	P13.13 Clinical factors involved in brain metastasis edema: results of a retrospective cohort and evaluation of the best edema descriptor. Neuro-Oncology, 2019, 21, iii65-iii65.	1.2	0
27	(R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study. Annals of Hematology, 2019, 98, 915-922.	1.8	7
28	MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS. Journal of Neuro-Oncology, 2018, 137, 463-468.	2.9	26
29	Cytomorphology and flow cytometry of brain biopsy rinse fluid enables faster and multidisciplinary diagnosis of large Bâ€cell lymphoma of the central nervous system. Cytometry Part B - Clinical Cytometry, 2018, 94, 182-188.	1.5	15
30	Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder. Revue Neurologique, 2018, 174, 675-679.	1.5	7
31	Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. Haematologica, 2018, 103, 1278-1287.	3.5	129
32	Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab. Emerging Infectious Diseases, 2018, 24, 1594-1596.	4.3	33
33	Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. Journal of Neuro-Oncology, 2017, 133, 315-320.	2.9	47
34	Vitreous microRNA levels as diagnostic biomarkers for vitreoretinal lymphoma. Blood, 2017, 129, 3130-3133.	1.4	33
35	Optic Nerve Infiltration in Primary Central Nervous System Lymphoma. JAMA Neurology, 2017, 74, 1368.	9.0	16
36	Une embûche de l'artère vertébrale. Pratique Neurologique - FMC, 2017, 8, 191-194.	0.1	0

Guido Ahle

#	Article	IF	CITATIONS
37	Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2016, 20, 282-291.	1.4	11
38	The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients. European Journal of Cancer, 2016, 61, 69-76.	2.8	66
39	Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro-Oncology, 2016, 18, 1297-1303.	1.2	135
40	Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma. Neuro-Oncology, 2016, 18, 361-367.	1.2	42
41	The French LOC Network for Primary CNS Lymphoma (PCNSL) Patients: What Can We Learn from a Large National Database?. Blood, 2016, 128, 926-926.	1.4	2
42	Superficial Siderosis, Traumatic Tap, and Xanthochromia. Archives of Neurology, 2012, 69, 791; author reply 791-2.	4.5	0
43	Intravascular Large B-Cell Lymphoma Presenting as Dementia and Hemolytic Anemia. Onkologie, 2010, 33, 174-177.	0.8	0
44	Successful treatment of hyperventilation-induced nystagmus in vestibular schwannoma with oxcarbacepine. Journal of Neurology, 2008, 255, 1093-1093.	3.6	3
45	Fulminant tumefactive multiple sclerosis: Therapeutic implications of histopathology. Journal of Neurology, 2008, 255, 1272-1273.	3.6	22
46	Acute left hemispheric syndrome with cortical lesions in a patient with secondary porphyrinuria. Journal of Neurology, 2005, 252, 983-984.	3.6	2
47	Transcranial magnetic stimulation as a provocation for epileptic seizures in multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, 475-476.	3.0	21
48	Diagnosis of multiple sclerosis: comparison of the Poser criteria and the new McDonald criteria. Acta Neurologica Scandinavica, 2004, 109, 385-389.	2.1	44
49	Shape changes in prefrontal, but not parieto-occipital regions: brains of schizophrenic patients come closer to a circle in coronal and sagittal view. Psychiatry Research - Neuroimaging, 2004, 132, 261-271.	1.8	14
50	Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. American Journal of Medical Genetics Part A, 2001, 105, 498-501.	2.4	56
51	Familial occurrence of tardive dyskinesia. Acta Psychiatrica Scandinavica, 2001, 104, 375-379.	4.5	25
52	Familial occurrence of tardive dyskinesia. Acta Psychiatrica Scandinavica, 2001, 104, 375-379.	4.5	79